Adrian Gottschlich: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
Adrian Gottschlich, Assistant Physician at LMU Klinikum München, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“I am very excited to see our case report now published in the New England Journal of Medicine (NEJM).
In this report, we describe the use of Blinatumomab in a young patient with severe, multi-refractory Immune Thrombocytopenia (ITP) and Antiphospholipid Syndrome (APS). Despite exhausting all approved and multiple off-label treatment options, the patient continued to suffer from recurrent bleeding episodes and life-threatening thrombotic complications.
After two cycles of blinatumomab, we observed a remarkable clinical response: stabilization of platelet counts allowing discontinuation of all platelet-stimulating agents, disappearance of both ITP and APS antibody titers, and a substantial improvement in the patient’s quality of life.
We are deeply grateful to our patient for the trust placed in us to explore this novel immunotherapeutic approach.
This work was made possible through generous support from Deutsche Forschungsgemeinschaft (DFG) -German Research Foundation, Else Kröner-Fresenius-Stiftung, Deutsche Krebshilfe, and Bayerisches Zentrum für Krebsforschung (BZKF) which alsoenabled us to perform additional translational analyses in this fascinating case.
Special thanks to Marion Subklewe, Michael von Bergwelt and Karsten Spiekermann for their clinical and scientific guidance,and to Gerhard Zugmaier for his valuable advice.
I am also very grateful to all co-authors (Veit Bücklein, Karim El-Marouk, Frank Ziemann, Thomas J., Christian Rausch, Gerulf Hänel, Christian Wichmann, Prof. Lars Lindner Sebastian Kobold) and our collaborators who have contributed to this work, including our colleagues from Medizinische Klinik I (Rainer Kaiser, Michael Schmid) and IV (Hendrik Schulze-Koops), the Department of Radiology (Michael Winkelmann) and the Department of Transfusion Medicine in Greifswald (Thomas Thiele, Stefan Handtke).
P.S.: Notably, the clinical response is ongoing after >9 months of follow-up.”
Rainer Kaiser, Internal Medicine and Cardiology Specialist at LMU Klinikum München, shared this post, adding:
“Fantastic work spearheaded by Dr. Adrian Gottschlich and Marion Subklewe, now out in NEJM Group. Remarkable reduction in platelet-binding antibodies, platelet activation, and sustained increases in platelet counts after BiTE treatment. Congratulations – we’re happy to have contributed!”
Title: Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome
Authors: Adrian Gottschlich, Veit Bücklein, Karim El-Marouk, Rainer Kaiser, Michael Schmid, Thomas Janert, Michael Winkelmann, Frank Ziemann, Gerulf Hänel, Stefan Handtke, Thomas Thiele, Christian Wichmann, Sebastian Kobold, Gerhard Zugmaier, Christian Rausch, Hendrik Schulze-Koops, Lars Lindner, Karsten Spiekermann, Michael von Bergwelt-Baildon, Marion Subklewe
Read the Full Article on New England Journal of Medicine.
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 15, 2026, 13:51Miguel Gómez Álvarez: Navigating the Complexities of Erythrocytosis and the Role of PIEZO1
-
Jun 15, 2026, 13:37Katja Sockel: EHA 2026 Inspires New Ideas and Global Connections
-
Jun 15, 2026, 13:25Srishti Goyal։ India’s Blood Donation Journey – Looking Beyond the Numbers
-
Jun 15, 2026, 13:22Debra BenAvram: Every Two Seconds – Someone Needs Blood
-
Jun 15, 2026, 13:13Christina Ornauer: Exploring the Latest Advances in Hematology at EHA 2026
-
Jun 15, 2026, 13:05Angelo Zanniti: Back from EHA 2026 Congress
-
Jun 15, 2026, 12:56Chiara Pirillo: Building Global Connections at EHA 2026
-
Jun 15, 2026, 12:50Marina Planas: MRD and Molecular Monitoring Take Center Stage at EHA 2026
-
Jun 15, 2026, 12:46Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026